These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 15843821

  • 1. High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.
    Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, Götze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L, Döhner K, Fröhling S, Döhner H, AML Study Group (AMLSG).
    Leukemia; 2005 Jun; 19(6):978-83. PubMed ID: 15843821
    [Abstract] [Full Text] [Related]

  • 2. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
    Esteve J, Escoda L, Martín G, Rubio V, Díaz-Mediavilla J, González M, Rivas C, Alvarez C, González San Miguel JD, Brunet S, Tomás JF, Tormo M, Sayas MJ, Sánchez Godoy P, Colomer D, Bolufer P, Sanz MA, Spanish Cooperative Group PETHEMA.
    Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
    [Abstract] [Full Text] [Related]

  • 3. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M, Lazzarino M, Bernasconi C.
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [Abstract] [Full Text] [Related]

  • 4. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
    Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F, GIMEMA Acute Leukaemia Working Party.
    Br J Haematol; 2011 Sep; 154(5):564-8. PubMed ID: 21751984
    [Abstract] [Full Text] [Related]

  • 5. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
    Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Büchner T, German AML Cooperative Group.
    Leukemia; 2009 Dec; 23(12):2248-58. PubMed ID: 19741727
    [Abstract] [Full Text] [Related]

  • 6. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 7. Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.
    Röllig C, Schäfer-Eckardt K, Hänel M, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U.
    Ann Hematol; 2015 Apr; 94(4):557-63. PubMed ID: 25366167
    [Abstract] [Full Text] [Related]

  • 8. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
    Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F.
    Blood; 2000 Aug 15; 96(4):1247-53. PubMed ID: 10942364
    [Abstract] [Full Text] [Related]

  • 9. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
    Haas R, Ho AD, Del Valle F, Fischer JT, Ehrhardt R, Döhner H, Witt B, Huberts H, Kaplan E, Hunstein W.
    Semin Oncol; 1993 Dec 15; 20(6 Suppl 8):20-6. PubMed ID: 8290968
    [Abstract] [Full Text] [Related]

  • 10. Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
    Finsinger P, Breccia M, Minotti C, Carmosino I, Girmenia C, Chisini M, Volpicelli P, Vozella F, Romano A, Montagna C, Colafigli G, Cimino G, Avvisati G, Petti MC, Lo-Coco F, Foà R, Latagliata R.
    Ann Hematol; 2015 Feb 15; 94(2):195-200. PubMed ID: 25186786
    [Abstract] [Full Text] [Related]

  • 11. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
    Eardley AM, Heller G, Warrell RP.
    Leukemia; 1994 Jun 15; 8(6):934-9. PubMed ID: 8207987
    [Abstract] [Full Text] [Related]

  • 12. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J, Shen ZX, Sun GL, Chen SJ, Wang ZY, Chen Z.
    Int J Hematol; 1999 Dec 15; 70(4):248-60. PubMed ID: 10643151
    [Abstract] [Full Text] [Related]

  • 13. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
    Zubizarreta PA, Rose AB, Felice MS, Alfaro E, Delfino S, Cygler AM, Sackmann-Muriel F.
    Pediatr Hematol Oncol; 2000 Mar 15; 17(2):155-62. PubMed ID: 10734658
    [Abstract] [Full Text] [Related]

  • 14. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
    Gupta V, Yi QL, Brandwein J, Lipton JH, Messner HA, Schuh AC, Wells RA, Minden MD.
    Leuk Res; 2005 Jan 15; 29(1):113-4. PubMed ID: 15541484
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. All-trans-retinoic acid in acute promyelocytic leukemia.
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH.
    N Engl J Med; 1997 Oct 09; 337(15):1021-8. PubMed ID: 9321529
    [Abstract] [Full Text] [Related]

  • 20. Therapy of molecular relapse in acute promyelocytic leukemia.
    Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F.
    Blood; 1999 Oct 01; 94(7):2225-9. PubMed ID: 10498592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.